{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Feyles E"],"funding":["MUR PNRR Extended Partnership Initiative on Emerging Infectious Diseases","Intesa Sanpaolo - Fondo di Beneficenza"],"pagination":["890"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12299477"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(7)"],"pubmed_abstract":["Cell-based phenotypic screening of a privileged in-house library composed of pyridobenzothiazolone (PBTZ) analogues was conducted against representative viruses responsible for common respiratory tract infections in humans, i.e., respiratory syncytial virus (RSV), human coronavirus type OC43 (HCoV-OC43), and influenza virus type A (IFV-A). We identified a compound with broad-spectrum inhibitory activity against multiple strains of RSV, HCoV, and IFV, with EC<sub>50</sub> values in the low micromolar range and cell-independent activity. Its antiviral activity and cytocompatibility were confirmed in a fully differentiated 3D model of the bronchial epithelium mimicking the in vivo setting. The hit compound enters cells and localizes homogeneously in the cytosol, inhibiting replicative phases "],"journal":["Viruses"],"pubmed_title":["Broad-Spectrum Antiviral Activity of Pyridobenzothiazolone Analogues Against Respiratory Viruses."],"pmcid":["PMC12299477"],"funding_grant_id":["PE00000007, INF-ACT","B/2022/0185"],"pubmed_authors":["Manfroni G","Civra A","Ritta M","Lembo D","Feyles E","Arduino I","Muratori L","Felicetti T","Raimondo S","Donalisio M"],"additional_accession":[]},"is_claimable":false,"name":"Broad-Spectrum Antiviral Activity of Pyridobenzothiazolone Analogues Against Respiratory Viruses.","description":"Cell-based phenotypic screening of a privileged in-house library composed of pyridobenzothiazolone (PBTZ) analogues was conducted against representative viruses responsible for common respiratory tract infections in humans, i.e., respiratory syncytial virus (RSV), human coronavirus type OC43 (HCoV-OC43), and influenza virus type A (IFV-A). We identified a compound with broad-spectrum inhibitory activity against multiple strains of RSV, HCoV, and IFV, with EC<sub>50</sub> values in the low micromolar range and cell-independent activity. Its antiviral activity and cytocompatibility were confirmed in a fully differentiated 3D model of the bronchial epithelium mimicking the in vivo setting. The hit compound enters cells and localizes homogeneously in the cytosol, inhibiting replicative phases ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2025-08-24T03:05:39.835Z","creation":"2025-08-24T03:05:39.835Z"},"accession":"S-EPMC12299477","cross_references":{"pubmed":["40733508"],"doi":["10.3390/v17070890"]}}